$RAPP effect size is yuge and AE profile much better than expected. catalyst desert for a while so prob dead money till next data, but could easily get scooped up pre-ph3 ala $LBPH. comfortable adding below $30. avg ~27ish
$JSPR looks like market starting to wake up to the huge valuation gap between JSPR and $CLDX. CLDX at $1.4B market cap and JSPR only $100M. If JSPR can demonstrate a better efficacy/safety profile than CLDX with this month's CSU key data, expect that gap to narrow considerably. Obv there are some nuances - CLDX having more cash, ahead in timeline, etc, but this is a similar setup to what happened with $DRUG and $LBPH. Assuming no dilution, a $1.4B market cap would be $93 for JSPR, 100% dilution would be $46. Things can get crazy with 15M O/S
@DevAd
-Official Data release with positive runore/leaks June 3rd
-Getting listed on nasdaq
-getting listed on more exchanges for retail investors like robinhood
-getting acquired based on good data like $LBPH had in a very similar scenario
-getting breakthrough device designation from the fda to come to market sooner and potnetially skipping more trials
-making headlines and big news for being first therapy to enable to nervous system to heal itself
-can be used along with NVG-300 to treat other markets and indications like MS, ALS, Stroke, Alzheimers
-Positive Preclinical data for NVG-300
TD Cowen🏁 $DRUG at a Buy rating, said lead asset BMB-101 is a biased 5-HT2C agonist that has the potential to be best in class (BiC) for the treatment of certain refractory seizure disorders.
$LBPH - $HLBBF
TD Cowen additionally said in its initiation report: "Bright Minds Bio is a biotechnology company developing next generation serotonin (5-HT) modulating drugs for the treatment of seizure, neurologic, and neuropsychiatric disorders.
Lead candidate BMB-101 is a highly selective and potent G-protein biased 5-HT2C receptor agonist currently in Ph. Il development for rare and refractory seizure disorders (absence/DEE).
Other 5-HT2C agonists have shown impressive anti-seizure activity; however, have limitations on dosing and durability. While development remains, BMB-101 has the potential to overcome these limitations.
Our KOLs have highlighted the need for additional and improved ASMs for both absence seizures and DEEs."
TD Cowen went on to say:
Chardan🏁 $DRUG Buy-$80, said "Leveraging Serotonin for Treating Epilepsy; Initiate with Buy; PT $80"
$LBPH - $HLBBF
Chardan said in its initiation report:
H.C. Wainwright, on 2/19, reiterated $DRUG Buy-$85 and said "we view Bright Minds as a differentiated player in the serotonergic epilepsy landscape with BMB-101 positioned as a potential best-in-class therapy pending Phase 2 data in 2Q25."
$HLBBF - $LBPH
H.C. Wainwright said in its note to investors:
Piper Sandler🏁 $DRUG Overweight-$93, says 'we are initiating coverage on Bright Minds Biosciences with an OW rating and $93 PT.'
$LBPH $HLBBF
"We believe its lead asset, BMB-101, is a differentiated G-protein biased 5-HT2C agonist positioned to drive sustained efficacy in drug-resistant epilepsies with clean safety.
In our view, the recent $2.6B acquisition of Longboard Pharmaceuticals (by H. Lundbeck A/S, not covered) validates the 5-HT2C agonist MoA value proposition with positive bexicaserin Ph1b/2a PACIFIC data driving strategic interest. As such, we see BMB-101 as a more potent 5-HT2C agonist compared to bexicaserin with no ß-arrestin recruitment.
Thus, we expect 2H25 topline from open-label Ph2 BREAKTHROUGH in n =~ 20 absence epilepsy or DEE patients to drive share movement and potentially close the ~$2.35B valuation gap in tandem with a growing portfolio of 5-HT assets."
@Immc With every "restructuring" ticker I've played, I've seen this. Restructuring as in buyout, gone private, selling, acquisition or whatever they want to call it etc... Can't explain it fully but my experience is institutions being told to enter but getting their shares off market. It's like all of a sudden the volume dies but the price keeps going up. I expect to see this trading in the thousands volume. A million is still high for what I've seen and compared to this float. But yes, there are more holders and sale/buy frequencies will go down along with the volume but the price will keep going up if there's merit. At a point they can even do offerings and the price will just go back to what it was. Other than BNTC, one other I played and just remembered was $LBPH. It's delisted now after the acquisition is complete but it was the same story. Honestly I'd love to see a LBPH outcome for $ITRM but I don't think it will be lifted that high.
$CADL CADL's potential, using a comparable biotech company. $LBPH . I just looked into thisd stock and the story goes something like this...
December 2023- Company is running a Phase 1b/2a clinical trial which evaluated bexicaserin for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Stock Price is ~$5
January 2023- Data is released and stock shoots up to ~$23 on good data. Study achieved its primary efficacy endpoint. Treatment with the drug achieved a median seizure reduction of 53.3% in the countable motor seizure frequency compared with 20.8% for those receiving placebo.
Jan 2024- Sept 2024- Stock price is slowly increasing and climbs to ~$30.
Sept 2024- Longboard initiated the phase III DEEp SEA study, which is evaluating bexicaserin for the treatment of seizures associated with DS in patients aged two years and older.
Oct 2023- were Acquired in Oct 2024 for $2.6B or $60/ share by Lundbeck.
